로딩 중…
지수 로딩 중…
Arvinas, Inc.
ARVN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$8.06+0.37%
2026-08-03
Financials
Valuation Metrics
Arvinas, Inc.'s Market Cap is $520M. At end of 2025 it was $770M. Ranked #2778 of 3,111 in US market (top 89%), #1204 of 1,445 on NASDAQ (top 83%), #222 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $520M | US#2,778/3,111 Sec#222/269 |
| Revenue | $89M | US#2,807/3,111 Sec#130/269 |
| Net Income | $-221M | US—/3,111 Sec—/269 |
| Total Assets | $648M | US#2,655/3,111 Sec#134/269 |
| Net Assets | $387M | US#2,427/3,111 Sec#141/269 |
| Value | ||
| P/B | 1.34x | US#679/3,111 Sec#31/269 |
| P/S | 5.82x | US#2,375/3,111 Sec#93/269 |
| FCF Yield | -49.40% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -57.21% | US#2,772/3,111 Sec#186/269 |
| ROA | -34.18% | US#2,907/3,111 Sec#176/269 |
| Op. Margin | -279.31% | US#2,883/3,111 Sec#150/269 |
| Revenue Growth | -91.74% | US#2,938/3,111 Sec#182/269 |
| Earnings Growth | -169.48% | US#2,200/3,111 Sec#78/269 |
| Financial Health | ||
| Debt Ratio | 67.40% | US#754/3,111 Sec#155/269 |
| Total Debt | $9M | US#2,828/3,111 Sec#207/269 |
| FCF | $-257M | US#2,771/3,111 Sec#230/269 |
| Cash | $87M | US#2,302/3,111 Sec#186/269 |
| Current Ratio | 5.44x | US#435/3,111 Sec#138/269 |
| Performance | ||
| 1Y Return | 8.63% | US#1,796/3,111 Sec#184/269 |
| 1M Return | -3.93% | US#1,803/3,111 Sec#119/269 |
| From 52W High | -44.45% | US#2,623/3,111 Sec#206/269 |
| 1Y MDD | -49.53% | US#2,384/3,111 Sec#184/269 |
| Trading | ||
| Volume | 706,620 shares | US#1,799/3,111 Sec#172/269 |
| Trading Value | $6M | US#2,602/3,111 Sec#216/269 |
| Per Share | ||
| EPS | $-1.24 | US—/3,111 Sec—/269 |
| BPS | $6.69 | US#2,072/3,111 Sec#108/269 |